Regeneron Pharmaceuticals, Inc. (REGN)

The company now

Regeneron reported third-quarter 2026 revenue of $5.1 billion on 30 October, up 36 percent from a year earlier 1. Net income under standard accounting rules was $1,949 million, up 33 percent 1.

Much of the gain came from Sanofi, which sells Dupixent: its collaboration revenue rose 68 percent to $2,724 million 1. Regeneron said its share of profits on antibodies, mainly Dupixent, reached $2.575 billion, and a balance it owed Sanofi no longer reduced that revenue 1. Healthcare Digital called it the third straight quarter of double-digit growth in both revenue and non-GAAP earnings per share 10.

In the eye business, EYLEA HD sales in the United States rose 62 percent to $699 million, while the older EYLEA fell 41 percent to $400 million as patients switched and biosimilar copies arrived 111. Management expects a further fall in EYLEA demand, in the low to mid teens in percent, in the fourth quarter 11.

Two events frame the next weeks 1. Regeneron expects an FDA decision in November on cemdisiran, a gene-silencing drug for the muscle disease myasthenia gravis 1. On 1 October it also added four long-acting antibodies to the Sanofi alliance for $1.0 billion up front and up to $7.0 billion in milestones 18.

As of Nov 3, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.